Discussion :
The fold increase in GMT was higher in test group as compared to control in all trials , indicating effective immunogenicity of CYD-TDV . Another trend found in all trials is that the third dose of CYD-TDV elicited only a slight increase in GMT from the second . Finally , patients in some trials
exhibited a more robust immune response ( higher peak GMT ) than others . These trials had higher baseline seropositivity rates , which led to stimulation of secondary immune response by the vaccine . Safety results were satisfactory in all trials in which most severe side effects were unrelated to the vaccine .
Conclusion :
CYD-TDV is both effective and safe for patients in endemic regions . This gives promise for further development and large-scale research on this vaccine to assess its efficacy in decreasing dengue prevalence and , its pervasive implementation in Indonesia .